---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009384"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:25:20.595843+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Collegium expands board, appoints Nancy Lurker as new director

## Summary
- Board expanded from 8 to 9 directors; Nancy Lurker appointed effective Feb 4, 2025.
- Lurker, 67, former CEO of EyePoint Pharmaceuticals, currently vice chair of EyePoint board.
- She will receive annual cash retainer of $50,000 (prorated) and equity award of $412,500 in RSUs vesting over 1 year.
- Board determined Lurker is independent under Nasdaq rules; no related party transactions.
- She also serves on boards of Alkermes (ALKS), Altasciences, and National Sanitation Foundation.

## SEC filing metadata
- accession: 0001104659-25-009384
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/tm255440d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009384
- JSON: https://secwatch.observer/filing/0001104659-25-009384.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009384.txt

## Key facts
- Executive change
  Nancy Lurker was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: appointed
  - Role: Director
  source text: approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.